Ron Cooper, Albireo CEO
Liver-focused startup nabs $115M in exchange for rare disease drug royalties
A Boston biotech focused on liver disease raised some quick cash last week, selling royalty rights to its sole FDA-approved drug.
Albireo Pharma sold the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
